6.4 References
［1］张彦收，刘运江.乳腺癌内分泌治疗简史.中华医史杂志，2015，45（1）.
［2］Waterman MR.Structural biology：Anticancer drug target pictured.Nature，2009，457（7226）：159-60.
［3］Veronesi U，Boyle P，Goldhirsch A，et al.Breast cancer.Lancet，2005，365（9472）：1727-41.
［4］Lintermans A，Vanderhaegen J，Neven P.Anastrozole and fulvestrant in metastatic breast cancer.N Engl J Med，2012，367（17）：1662；author reply 1663-1664.
［5］刘萍，边强.乳腺癌治疗药氟维司群（fulvestrant）.世界临床药物，2004，（01）：62-63.
［6］中国乳腺癌新辅助治疗专家组.中国乳腺癌新辅助治疗专家共识（2019年版）.中国癌症杂志，2019，29（5）.
［7］中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范（2017年版）.中国癌症杂志，2017，27（09）：695-759.
［8］Regan MM，Francis PA，Pagani O，et al.Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive，Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer：TEXT and SOFT Trials.J Clin Oncol，2016，34（19）：2221-2231.
［9］Pagani O，Regan MM，Francis PA.Are SOFT and TEXT results practice changing and how.Breast，2016，27：122-125.
［10］Hoefkens F，Dehandschutter C，Somville J，et al.Soft tissue sarcoma of the extremities：pending questions on surgery and radiotherapy.Radiat Oncol，2016，11（1）：136.(https://www.daowen.com)
［11］Valsecchi ME，Recondo G，de la Vega M，et al.Anti-Hormonal Therapies for Premenopausal Patients--What did we Learn from the TEXT/SOFT Trials.Rev Recent Clin Trials，2015，10（2）：90-100.
［12］Chlebowski RT.Interpreting quality-of-life data from the SOFT and TEXT trials.Lancet Oncol，2015，16（7）：749-751.
［13］Regan MM，Walley BA，Francis PA，et al.Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer：an exploratory analysis of TEXT and SOFT.Ann Oncol，2017，28（9）：2225-2232.
［14］Saha P，Regan MM，Pagani O，et al.Treatment Efficacy，Adherence，and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFTAdjuvant Endocrine Therapy Trials.J Clin Oncol，2017，35（27）：3113-3122.
［15］武正炎.ER阳性绝经后乳腺癌术后辅助内分泌治疗（BIG1-98研究结果解读）.实用临床医药杂志，2006，（03）：32-33+39.
［16］Thürlimann B，Keshaviah A，Coates AS，et al.A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.N Engl J Med，2005，353（26）：2747-2757.
［17］Regan MM，Neven P，Giobbie-Hurder A，et al.Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer：the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.Lancet Oncol，2011，12（12）：1101-1108.
［18］Mouridsen H，Giobbie-Hurder A，Goldhirsch A，et al.Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.N Engl J Med，2009，361（8）：766-776.
［19］Regan MM，Price KN，Giobbie-Hurder A，et al.Interpreting Breast International Group（BIG）1-98：a randomized，double-blind，phase Ⅲ trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive，early breast cancer.Breast Cancer Res，2011，13（3）：209.
［20］Rasmussen BB，Regan MM，Lykkesfeldt AE，et al.Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer：supplementary results from the BIG 1-98 randomised trial.Lancet Oncol，2008，9（1）：23-28.